IO Biotech Inc (IOBT) - Total Assets
Based on the latest financial reports, IO Biotech Inc (IOBT) holds total assets worth $39.96 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See IOBT net asset quality score to measure how much of total assets are equity-financed.
IO Biotech Inc - Total Assets Trend (2019–2024)
This chart illustrates how IO Biotech Inc's total assets have evolved over time, based on quarterly financial data. Check IO Biotech Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
IO Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
IO Biotech Inc's total assets of $39.96 Million consist of 95.9% current assets and 4.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 88.7% |
| Accounts Receivable | $1.13 Million | 1.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how IO Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IO Biotech Inc (IOBT) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: IO Biotech Inc's current assets represent 95.9% of total assets in 2024, a decrease from 99.8% in 2019.
- Cash Position: Cash and equivalents constituted 88.7% of total assets in 2024, up from 83.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.
IO Biotech Inc Competitors by Total Assets
Key competitors of IO Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
IO Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.01 | 5.37 | 1.85 |
| Quick Ratio | 2.01 | 5.37 | 1.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $18.52 Million | $70.19 Million | $2.58 Million |
IO Biotech Inc - Advanced Valuation Insights
This section examines the relationship between IO Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.34 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -55.1% |
| Total Assets | $67.70 Million |
| Market Capitalization | $611.57K USD |
Valuation Analysis
Below Book Valuation: The market values IO Biotech Inc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: IO Biotech Inc's assets decreased by 55.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for IO Biotech Inc (2019–2024)
The table below shows the annual total assets of IO Biotech Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $67.70 Million | -55.08% |
| 2023-12-31 | $150.72 Million | -0.72% |
| 2022-12-31 | $151.81 Million | -31.71% |
| 2021-12-31 | $222.29 Million | +3832.21% |
| 2020-12-31 | $5.65 Million | -40.01% |
| 2019-12-31 | $9.42 Million | -- |
About IO Biotech Inc
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand … Read more